Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTANASDAQ:MGTXNASDAQ:TRMLNASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTAEnanta Pharmaceuticals$5.50-1.9%$6.22$4.09▼$17.24$116.27M0.69285,173 shs141,430 shsMGTXMeiraGTx$6.54+0.7%$6.54$3.85▼$8.75$515.32M1.21321,255 shs138,615 shsTRMLTourmaline Bio$17.23-3.3%$14.63$11.56▼$29.79$440.63M2.14275,262 shs93,742 shsURGNUroGen Pharma$10.04-1.6%$10.46$8.94▼$20.70$462.55M0.8418,074 shs336,866 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTAEnanta Pharmaceuticals+1.82%+13.59%-9.68%+1.08%-57.41%MGTXMeiraGTx+3.51%+21.99%-15.60%+6.92%+31.64%TRMLTourmaline Bio+2.89%+22.73%+1.19%+1.77%+18.09%URGNUroGen Pharma+1.49%-1.83%-14.29%+0.49%-29.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTAEnanta Pharmaceuticals3.8973 of 5 stars3.41.00.04.72.64.20.0MGTXMeiraGTx4.663 of 5 stars3.54.00.04.82.72.51.9TRMLTourmaline Bio2.3637 of 5 stars3.53.00.00.02.52.50.0URGNUroGen Pharma4.2003 of 5 stars4.52.00.04.51.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25213.92% UpsideMGTXMeiraGTx 3.00Buy$24.50274.90% UpsideTRMLTourmaline Bio 3.00Buy$49.33186.32% UpsideURGNUroGen Pharma 3.00Buy$32.86227.43% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, MGTX, URGN, and TRML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/17/2025URGNUroGen PharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$22.00 ➝ $16.004/16/2025URGNUroGen PharmaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$23.003/17/2025MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$11.00 ➝ $13.003/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.003/11/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $55.003/10/2025URGNUroGen PharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/6/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$42.002/25/2025URGNUroGen PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$64.00 ➝ $64.002/24/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTAEnanta Pharmaceuticals$66.59M1.76N/AN/A$5.24 per share1.05MGTXMeiraGTx$33.28M15.48N/AN/A$2.17 per share3.01TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/AURGNUroGen Pharma$90.40M5.12N/AN/A($2.78) per share-3.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%5/5/2025 (Estimated)MGTXMeiraGTx-$84.03M-$2.13N/A17.200.37-633.05%-146.38%-53.05%5/8/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$2.87N/AN/AN/AN/A-20.97%-20.56%5/12/2025 (Estimated)URGNUroGen Pharma-$102.24M-$3.23N/AN/AN/A-129.11%N/A-47.94%5/12/2025 (Estimated)Latest ENTA, MGTX, URGN, and TRML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025TRMLTourmaline Bio-$0.91N/AN/AN/AN/AN/A5/12/2025Q1 2025URGNUroGen Pharma-$0.83N/AN/AN/A$22.71 millionN/A5/8/2025Q1 2025MGTXMeiraGTx-$0.38N/AN/AN/A$4.44 millionN/A5/5/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.16N/AN/AN/A$15.96 millionN/A3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 million3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 million3/10/2025Q4 2024URGNUroGen Pharma-$0.69-$0.80-$0.11-$0.80$25.25 million$24.57 million2/10/2025Q1 2025ENTAEnanta Pharmaceuticals-$1.16-$1.05+$0.11-$1.05$17.25 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/AURGNUroGen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTAEnanta PharmaceuticalsN/A5.475.47MGTXMeiraGTx0.862.342.34TRMLTourmaline BioN/A40.3340.33URGNUroGen Pharma4.779.008.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTAEnanta Pharmaceuticals94.99%MGTXMeiraGTx67.48%TRMLTourmaline Bio91.89%URGNUroGen Pharma91.29%Insider OwnershipCompanyInsider OwnershipENTAEnanta Pharmaceuticals13.89%MGTXMeiraGTx8.40%TRMLTourmaline Bio11.02%URGNUroGen Pharma5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableMGTXMeiraGTx30078.86 million71.59 millionOptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableURGNUroGen Pharma20046.09 million22.26 millionOptionableENTA, MGTX, URGN, and TRML HeadlinesRecent News About These CompaniesSilverarc Capital Management LLC Buys 219,344 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)April 24 at 7:35 AM | marketbeat.com50,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Diadema Partners LPApril 24 at 7:17 AM | marketbeat.comThe Goldman Sachs Group Issues Pessimistic Forecast for UroGen Pharma (NASDAQ:URGN) Stock PriceApril 20, 2025 | americanbankingnews.comAlliancebernstein L.P. Buys 175,859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)April 19, 2025 | marketbeat.comScotiabank Initiates Coverage on UroGen Pharma (NASDAQ:URGN)April 18, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Ligand Pharma (LGND)April 17, 2025 | markets.businessinsider.comUroGen Pharma initiated with an Outperform at ScotiabankApril 17, 2025 | markets.businessinsider.comScotiabank Initiates Coverage of UroGen Pharma (URGN) with Sector Outperform RecommendationApril 17, 2025 | msn.comThis UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayApril 16, 2025 | benzinga.comExodusPoint Capital Management LP Acquires New Shares in UroGen Pharma Ltd. (NASDAQ:URGN)April 15, 2025 | marketbeat.comUroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong BuyApril 12, 2025 | seekingalpha.comUroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from AnalystsApril 12, 2025 | marketbeat.comTrexquant Investment LP Has $1.84 Million Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)April 11, 2025 | marketbeat.comWhy UroGen Pharma Ltd.’s (URGN) Stock Is Down 10.84%April 10, 2025 | aaii.comUroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - Here's WhyApril 4, 2025 | marketbeat.comUroGen Pharma price target lowered to $55 from $64 at H.C. WainwrightMarch 11, 2025 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | insidermonkey.comUroGen Pharma sees FY25 operating expenses $215M-$225MMarch 10, 2025 | markets.businessinsider.comUrogen pharma outlines $1B revenue potential for UGN-102 with June 2025 launch targetMarch 10, 2025 | msn.comUroGen Pharma Ltd. (URGN) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | seekingalpha.comUrogen Pharma (URGN) Reports Q4 Loss, Lags Revenue EstimatesMarch 10, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off AnywayJPMorgan: The 'NVIDIA of Banking' Poised for More Gains?By Gabriel Osorio-Mazilli | March 28, 2025View JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?Top 3 S&P 500 Winners in a Losing MarketBy Ryan Hasson | April 9, 2025View Top 3 S&P 500 Winners in a Losing MarketOil Prices Are Tanking—These 3 Plays Could Fuel Your GainsBy Gabriel Osorio-Mazilli | April 9, 2025View Oil Prices Are Tanking—These 3 Plays Could Fuel Your GainsENTA, MGTX, URGN, and TRML Company DescriptionsEnanta Pharmaceuticals NASDAQ:ENTA$5.50 -0.11 (-1.88%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.MeiraGTx NASDAQ:MGTX$6.54 +0.05 (+0.69%) As of 02:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Tourmaline Bio NASDAQ:TRML$17.23 -0.59 (-3.31%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.UroGen Pharma NASDAQ:URGN$10.04 -0.17 (-1.62%) As of 02:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? 4 Reasons Enphase Downtrend Won’t End in 2025; 1 That It Will Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
